Improving the Ocular to Systemic Ratio of Topical Timolol by Varying the Dosing Time

Shigehiro Ohdo,* George M. Grass,† and Vincent H. L. Lee‡

This study was performed to determine whether the ratio of ocular to systemic absorption of topically applied timolol in the pigmented rabbit can be maximized by varying the time of drop instillation. Twenty-five microliters of 0.65% timolol maleate solutions were instilled into the pigmented rabbit eye at 6 AM, 12 PM, 6 PM, or 12 AM. The time course of timolol concentration in plasma and various eye tissues (conjunctiva, sclera, corneal epithelium, corneal stroma, aqueous humor, iris–ciliary body, and lens) was monitored with the use of reversed phase high-performance liquid chromatography (HPLC). Ocular timolol concentrations were approximately twice as high when the drug was administered at 12 PM than at 6 AM, 6 PM, or 12 AM, whereas timolol concentration in plasma was lowest when the drug was administered at 12 PM. It may, therefore, be possible to maximize the therapeutic index of topically applied timolol by administering the drug at 12 PM. Moreover, the possible influence of dosing time on the extent of ocular and systemic drug absorption must be considered when planning dosing schedules for topically applied ophthalmic drugs. Invest Ophthalmol Vis Sci 32:2790–2798, 1991

Absorption of topically applied drugs via the conjunctival and nasal mucosae into the blood stream to elicit side effects has been recognized as a possibility in ocular drug therapy for more than 25 years.1 Examples of these drugs include anticholinesterase agents,2 epinephrine,3–5 phenylephrine,6 and steroids.8 Depending on the physiochemical properties of the drug, varying extents of systemic drug absorption can occur. These extents range from 3% for inulin7 to approximately 80% for timolol.8 Nevertheless, the possibility of systemic drug absorption was not considered in various attempts to optimize ocular drug therapy until beta-blockers were widely used in patients with glaucoma.9 Several approaches have been investigated relative to reducing systemic drug absorption, and the results have been positive. These approaches include nasolacrimal occlusion with or without eyelid closure,10,11 use of microdrops,12 use of vehicles with extended residence time in the conjunctival sac,12,13 coadministration of vasoconstrictors such as phenylephrine and epinephrine,14 use of soft drugs that are rapidly inactivated once they are absorbed into the bloodstream,15 and use of prodrugs that are either inherently poorly absorbed into the bloodstream16 or are well absorbed across the cornea, thus permitting the use of a lower dose.17 Several of the approaches described above, notably those of vehicles and prodrugs, have also been investigated for improvement in ocular drug absorption.18

This study was conducted to evaluate the alternative strategy of varying the time of drop instillation to minimize the systemic absorption of topically applied timolol, a nonselective β-adrenergic blocking drug widely used in the treatment of glaucoma.9 This strategy was based on the expectation that drug absorption into the eye and the bloodstream is governed by a circadian rhythm, as is the case for intraocular pressure19–24 and for pharmacokinetic processes elsewhere in the body.25 For convenience, four dosing times were chosen: 6 AM, 12 PM, 6 PM, and 12 AM. The pigmented rabbit was the experimental animal. All experiments conformed with the ARVO Resolution on the Use of Animals in Research.

Materials and Methods

Male, Dutch-belted, pigmented rabbits, weighing 2.0–2.5 kg, were purchased from American Rabbity (Los Angeles, CA). The animals were housed in standard laboratory rabbit cages, with food and water ad libitum, in a light-controlled room at a temperature of 22 ± 1°C and humidity of 55 ± 10%. They were entrained to a lighting schedule of alternating 12-hr periods of light and dark (12L:12D) for at least 1 week before use. Lights were turned on at 6 AM and off at 6 PM. Experiments during the dark period were conducted under lighting conditions provided by Bright...
Lab Jr. Safelight bulbs (Delta 1, Dallas, TX), which are used primarily in photographic dark rooms and which emit a narrow visible spectrum in the far red range. Timolol maleate and propranolol HCl were purchased from Sigma Chemical Company (St. Louis, MO). Dosing solutions that contained 0.65% timolol maleate, equivalent to 0.5% timolol, were prepared in 10 mM Tris buffer and were adjusted to pH 7.4 with 10 N sodium hydroxide and rendered isotonic by adding sodium chloride. The commercial preparation was not used to avoid the possible confounding variables of acidic pH and benzalkonium chloride in the commercial formulation on the circadian rhythms of ocular and systemic absorption of timolol.

Assay

Timolol was quantitated with the use of reversed phase high-performance liquid chromatography (HPLC) on a Beckman UltraspHERE ODS column (25 cm × 4.6 mm, 5-μm particle size) fitted with a Brownlee Labs Newguard precolumn (1.5 cm) (West Coast Scientific, Hayward, CA), as previously described. The HPLC system consisted of an SCL-6A system controller, two LC-6A pumps, an SIL-6A autoinjector, an SPD-6A spectrophotometric detector, and a CRI-3A integrator (Shimadzu Instruments, Baltimore, MD). The mobile phase was a mixture that consisted of 4 parts of 10% acetonitrile in methanol and 6 parts of 0.2% triethylamine HCl in 5% acetonitrile at pH 3. The flow rate was 1 ml min⁻¹. Propranolol HCl (10 μg ml⁻¹) was used as the internal standard. Timolol was monitored at 294 nm. The retention time was 5 min for timolol and 12 min for propranolol. The sensitivity of the assay was more than 5 nmol with respect to timolol in a 2-ml plasma sample. The intra- and inter-run variations were 5% and 7.5%, respectively.

At the time of assay, an aqueous humor sample was mixed with an equal volume of acetonitrile that contained 0.01 N HCl and 10 mg ml⁻¹ propranolol HCl. After centrifugation, 80–120 μl of the supernatant was injected into the HPLC. Excised tissues were soaked in 200 μl of 0.6% HC1O₄ at 8°C for 12 hr. After centrifugation, 80–120 μl of the supernatant was mixed with an equal volume of acetonitrile that contained 0.2N HCl, vortexed for 3 min, and centrifuged at 1500Xg for 10 min. The upper organic layer was transferred to a 15-ml screw-capped conical centrifuge tube that contained 200 μl of 0.2N HCl, vortexed for 3 min, and centrifuged at 1500Xg for 10 min. The organic phase was discarded, and 100–120 μl of the aqueous phase that contained timolol and propranolol was injected into the HPLC. The same procedure was used to extract timolol from 2 ml of plasma. The extraction efficiency was greater than 75% for ocular tissue and plasma samples. Under these conditions, unbound and protein-bound timolol were extracted, and only unmetabolized timolol was measured.

Ocular Absorption of Topically Applied Timolol

At 6 AM, 12 PM, 6 PM, or 12 AM, 25 μl of a dosing solution was instilled directly into the corneas of each rabbit, collecting in the cul-de-sacs. At 5, 15, 30, 60, 90, 150, 180, or 240 min after dosing, each rabbit was killed with an overdose of a sodium pentobarbital solution (Eutha-6, Western Medical Supply, Arcadia, CA) administered via a marginal ear vein. After the corneal and conjunctival surfaces were thoroughly rinsed with 1.17% KC1 solution and were blotted dry, the corneal epithelium was scraped with a No. 11 scalpel. About 100–200 μl of aqueous humor was aspirated from the anterior chamber with a 1-ml tuberculin syringe fitted with a 27-gauge needle. The corneal stroma was excised by cutting at the corneolimbal margin. The iris and ciliary body were difficult to separate and were therefore removed as one piece. The lens was separated from the vitreous humor, which was discarded. The anterior sclera was dissected and trimmed to remove other tissue fragments. Finally, 8–10-mm tangential sections of conjunctiva were dissected from the upper and lower eyelids. Dissection was completed within 10 min for both eyes. All excised tissues were rinsed with ice-cold KCl solution, were blotted dry, were transferred to preweighed microcentrifuge tubes that contained 200 μl of 0.6% HClO₄, and were stored at −70°C. Four to eight eyes were used per time point per dosing period. Both eyes of a given rabbit were used.

Systemic Absorption of Topically Applied Timolol

The dosing procedure was as described above in the ocular absorption experiments. Fifteen minutes before the solution was instilled, the rabbits were cannuulated in a central ear artery with polyethylene tubing (PE-50, Intramedic) and were heparinized with 1000 U of Na heparin (Western Medical Supply, Arcadia, CA). Thereafter, 25 μl of a dosing solution was instilled into each eye of a given rabbit. At 0, 3, 6, 10, 15, 30, 45, 60, 90, and 120 min after dosing, 4-ml blood samples were collected into heparinized tubes and stored in the refrigerator until extraction of the drug the next day. The volume of blood that was aspirated was replenished with an equal volume of lactated Ringer’s solution, USP (Abbott Laboratories, Chicago, IL). Preliminary experiments showed that the plasma-timolol concentration was below the detec-
Fig. 1. Concentration–time profiles of timolol in the conjunctiva (plot A), anterior sclera (plot B), corneal epithelium (plot C), corneal stroma (plot D), aqueous humor (plot E), iris–ciliary body (plot F), lens (plot G), and plasma (plot H) of the pigmented rabbit following the topical instillation of 25 μl of 0.65% timolol maleate solutions at 0600, 1200, 1800, and 2400 hr. Error bars represent standard error for n = 4–8 at each dosing time. One-way ANOVA revealed statistically significant difference at P < 0.05 for the majority of time points among the four dosing times. The exceptions were 15 min in the conjunctiva; 15 and 60 min in the sclera; 5, 60, and 150 min in the corneal epithelium; 5 min in the corneal stroma; 5 min in the aqueous humor; 15 min in the iris–ciliary body; and 90, 180, and 240 min in the lens.
tion limit after 120 min; hence, blood was collected until then. The blood was centrifuged at 1500× g for 10 min to yield 2 ml of plasma, and then was frozen and stored at −20°C until assayed. At least four rabbits were used per dosing time, and rabbits were not reused.

**Time Course of Plasma–Timolol Concentration After Intravenous Administration at Various Dosing Times**

Fifty microliters of a 0.65% timolol maleate solution was injected into the marginal ear vein of pigmented rabbits at 6 AM, 12 PM, 6 PM, or 12 AM. The sampling schedule and sampling processing procedures were the same as in the topical solution instillation experiment described above. At least four rabbits were used per dosing time, and rabbits were not reused.

**Pharmacokinetic Data Analysis**

The data were plotted as timolol concentration vs time, and were subjected to noncompartmental pharmacokinetic analysis. The following pharmacokinetic parameters were obtained: peak time (tmax), peak timolol concentration (Cmax), area under the concentration–time curve (AUC), and mean residence time (MRT). The plasma data from the intravenous administration experiment were fitted to a two-compartment model to yield the pharmacokinetic parameters Cmax, AUC, and MRT. The extent of timolol absorption into the anterior segment tissues, expressed as AUC, was dependent on the time of dosing. For the majority of time points, one-way ANOVA showed a statistical difference at P < 0.05 in timolol concentrations in a given tissue among the four dosing times. In all anterior segment tissues except the lens, timolol concentrations were highest from 12 PM dosing, followed by either 6 PM or 12 AM dosing, and then by 6 AM dosing (Fig. 2). Moreover, an approximately two-fold difference was seen in ocular tissue concentrations between 6 AM and 12 PM dosing for the majority of time points (P < 0.05 by Fisher’s PLSD test). As shown in Figure 3, the AUC in the aqueous humor correlated well with that in the corneal epithelium and iris–ciliary body. This finding suggests that changes in timolol concentrations in the iris–ciliary body as a function of dosing time were due to changes in timolol concentrations in the aqueous humor, which were due to changes in timolol concentrations in the corneal epithelium.

In the plasma, timolol concentrations reached a peak within 6–10 min, regardless of dosing time (Fig. 1H and Table 1). Like ocular timolol absorption, systemic timolol absorption, expressed as Cmax and AUC, was also dependent on the dosing time (P < 0.008 by ANOVA). On the basis of the AUC shown in Figure 2H, absorption of timolol into the bloodstream was most extensive at 6 AM dosing, then at 6 PM, 12 AM, and 12 PM dosing, respectively. An 1.8-fold difference was seen in the plasma AUC between 6 AM and 12 PM dosing (P < 0.05 by Fisher’s PLSD test) (Table 1). The important observation was the negative correlation between ocular and systemic absorption on the basis of AUCs in the aqueous humor/iris–ciliary body and the plasma, respectively, as shown in Figure 4. Specifically, dosing at 12 PM afforded the best ocular absorption and the poorest systemic absorption, a desirable situation from a therapeutic point of view.

After intravenous administration, diurnal changes in the disappearance of timolol in the plasma were also seen, as shown in Figure 5. The AUC was the highest at 12 PM dosing, then at 6 AM, 12 AM, and 6 PM dosing (P < 0.05 by ANOVA) (Table 2). The Fisher’s PLSD test showed a statistical difference in plasma AUC between 12 PM dosing and the other three dosing times, but no statistical difference among these three dosing times at P < 0.05. As shown in Table 2, time-dependent changes were probably due to changes in the volume of distribution at steady state (Vdss) and the distribution rate constants k12 and k21, rather than to changes in the elimination rate constant (k10) of timolol from plasma according to two-compartment pharmacokinetic analysis.
Table 1. Pharmacokinetic parameters for changes in timolol concentration in plasma and various anterior segment tissues following topical dosing of 25 \( \mu \)l of 0.65% timolol maleate solutions to each eye

<table>
<thead>
<tr>
<th>Parameter*</th>
<th>Clock hr</th>
<th>Plasma</th>
<th>Conj.</th>
<th>Sclera</th>
<th>CE</th>
<th>CS</th>
<th>AH</th>
<th>ICB</th>
<th>Lens</th>
</tr>
</thead>
<tbody>
<tr>
<td>( t_{\text{max}} ) (min)</td>
<td>0600</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>15</td>
<td>90</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1200</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>15</td>
<td>150</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1800</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>30</td>
<td>90</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2400</td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>30</td>
<td>150</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>( C_{\text{max}} ) (ng/ml for plasma, ( \mu )g/ml for AH, or ( \mu )g/g for tissues)</td>
<td>0600</td>
<td>47.45</td>
<td>12.42</td>
<td>2.96</td>
<td>118.9</td>
<td>52.13</td>
<td>1.35</td>
<td>18.35</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>1200</td>
<td>37.25</td>
<td>29.19</td>
<td>3.15</td>
<td>183.5</td>
<td>50.39</td>
<td>3.83</td>
<td>28.30</td>
<td>0.27</td>
</tr>
<tr>
<td></td>
<td>1800</td>
<td>55.83</td>
<td>19.50</td>
<td>2.46</td>
<td>157.6</td>
<td>41.73</td>
<td>2.63</td>
<td>24.34</td>
<td>0.28</td>
</tr>
<tr>
<td></td>
<td>2400</td>
<td>55.87</td>
<td>22.45</td>
<td>3.44</td>
<td>139.4</td>
<td>40.35</td>
<td>1.54</td>
<td>30.10</td>
<td>0.34</td>
</tr>
<tr>
<td>( AUC ) (( \mu )g \times \text{min}/ml or ( \mu )g \times \text{min}/g)</td>
<td>0600</td>
<td>2.44</td>
<td>191.78</td>
<td>104.8</td>
<td>5392.1</td>
<td>1741.0</td>
<td>151.5</td>
<td>3143.1</td>
<td>22.40</td>
</tr>
<tr>
<td></td>
<td>1200</td>
<td>1.34</td>
<td>434.93</td>
<td>210.9</td>
<td>9891.8</td>
<td>3126.8</td>
<td>334.5</td>
<td>5369.0</td>
<td>19.95</td>
</tr>
<tr>
<td></td>
<td>1800</td>
<td>2.13</td>
<td>346.75</td>
<td>156.4</td>
<td>8855.7</td>
<td>2415.8</td>
<td>252.4</td>
<td>4120.2</td>
<td>20.25</td>
</tr>
<tr>
<td></td>
<td>2400</td>
<td>2.05</td>
<td>360.10</td>
<td>139.0</td>
<td>7347.1</td>
<td>1918.7</td>
<td>199.4</td>
<td>4131.0</td>
<td>24.90</td>
</tr>
<tr>
<td>MRT (min)</td>
<td>0600</td>
<td>46.7</td>
<td>59.24</td>
<td>73.22</td>
<td>75.25</td>
<td>73.70</td>
<td>88.21</td>
<td>128.42</td>
<td>107.95</td>
</tr>
<tr>
<td></td>
<td>1200</td>
<td>39.5</td>
<td>46.92</td>
<td>74.10</td>
<td>71.64</td>
<td>70.08</td>
<td>70.72</td>
<td>127.28</td>
<td>71.72</td>
</tr>
<tr>
<td></td>
<td>1800</td>
<td>41.6</td>
<td>39.70</td>
<td>65.33</td>
<td>71.19</td>
<td>70.45</td>
<td>76.18</td>
<td>127.51</td>
<td>90.14</td>
</tr>
<tr>
<td></td>
<td>2400</td>
<td>40.9</td>
<td>42.05</td>
<td>69.68</td>
<td>57.52</td>
<td>70.26</td>
<td>87.70</td>
<td>127.66</td>
<td>71.59</td>
</tr>
</tbody>
</table>

* See text for explanation of abbreviations. Key: Conj, conjunctiva; CE, corneal epithelium; CS, corneal stroma; AH, aqueous humor; ICB, iris-ciliary body.

Discussion

This study shows, for the first time, that ocular and systemic absorption of topically applied ophthalmic drugs may be influenced by the time of drop instillation. In the pigmented rabbit, absorption of topically applied timolol into the eye at 12 PM, as shown by AUC, was about two times greater than at 6 AM, 6 PM, or 12 AM. Interestingly, at 12 PM, the extent of ocular absorption was best, the extent of absorption of topically applied timolol into the bloodstream was worst. If this trend prevails in humans, the ratio of ocular to systemic absorption of topically applied timolol could be maximized, thereby improving its safety, by judiciously selecting the time of drop instillation.

It may be possible to minimize drug toxicity by optimizing the time of drug administration. The rationale is that receptor density,27 drug absorption, metabolism, and excretion25 may vary at different times during the day.28-30 Thus, cisplatin was 25% less nephrotic when given at 6 PM, presumably when the patient's urine flow was highest.31 As another example, intraperitoneally administered valproic acid in ICR male mice was more toxic when injected at 5 PM and least toxic when injected at 9 AM or 1 PM,32 probably due to rhythmic changes in sensitivity of the central nervous system to the drug. However, this situation concerning timolol is complicated by the fact that, in rabbits, maximum ocular absorption occurs at the time when intraocular pressure is not the most responsive to timolol.24 This could be true in humans, although humans have diurnal rhythms of intraocular pressure.24,33 and aqueous flow34 that are approximately 180° out of phase with these rhythms in rabbits.

Concentrations in the aqueous humor and iris-ciliary body, particularly between 6 AM and 12 PM, may be attributed to corresponding changes in precorneal drug loss, corneal drug penetration, or drug elimination from the target tissue/fluid. One-compartment pharmacokinetic analysis of the data in the elimination phase in aqueous humor (Fig. 1E) shows a rate constant of 0.82 ± 0.18 min⁻¹ at 6 AM, 1.33 ± 0.26 min⁻¹ at 12 PM, 1.11 ± 0.17 min⁻¹ at 6 PM, and 1.51 ± 0.85 min⁻¹ at 12 AM (P < 0.025 by ANOVA). Thus, elimination of timolol from the aqueous humor is about 60% slower at 6 AM than at 12 PM (P
Fig. 2. Area under the concentration–time curves (AUC) of timolol in the conjunctiva (plot A), anterior sclera (plot B), corneal epithelium (plot C), corneal stroma (plot D), aqueous humor (plot E), iris–ciliary body (plot F), lens (plot G), and plasma (plot H) of the pigmented rabbit following the topical instillation of 25 μl of 0.65% timolol maleate solutions at 0600, 1200, 1800, and 2400 hr. Error bars represent standard error for n = 4–8. No error bars were shown for the ocular tissues since pooled data were used.
< 0.01 by Fisher's PLSD test.) Although the slower rate of timolol clearance from the aqueous humor at 6 AM is consistent with the slower aqueous humor flow rate at that time, it is inconsistent with the lower aqueous humor concentration achieved at 6 AM dosing (Fig. 1E), because a higher aqueous humor drug concentration would be expected. Consequently, diurnal variations in precorneal clearance or corneal permeability are plausible explanations.

Work completed in the corresponding author’s laboratory showed that corneal permeability to timolol at 12 PM (1.13 ± 0.06 × 10^-5 cm s^-1) was about 30% greater than at 6 AM (0.87 ± 0.09 × 10^-5 cm s^-1) (unpublished data). Clearly, this magnitude of increase alone cannot account for the two-fold difference in extent of timolol absorption into the eye. It thus appears that time-dependent changes in precorneal drug loss, a major component of which is solution drainage, play a more important role. Although no information exists on how the solution drainage or how the tear flow rate varies during a 24-hr period, there is evidence that, in human subjects, tear enzymes, proteins, Ca^2+, pH, and osmotic pressure, show diurnal variations. Some of these factors, such as pH, osmolality, and protein concentration, alter ocular drug bioavailability.

Because solution drainage determines the rate at which the administered dose reaches the nasal cavity from which more than 70% of an instilled dose of timolol is absorbed, it is not surprising that time-dependent changes in systemic absorption bear an opposite trend to those seen in ocular absorption (Fig. 4). Like corneal permeability, nasal permeability to timolol may vary with time, being lower at 12 PM than at 6 AM. This possibility is suggested indirectly by the time-dependent changes in plasma-timolol pharmacokinetics after intravenous administration (Fig. 5 and Table 2). Plasma-timolol concentrations were highest at 12 PM than at other dosing times. This finding is directly opposite to the trend afforded by topical solution instillation (Fig. 1H). The higher timolol concentrations achieved after intravenous administration at 12 PM were probably due to slower drug clearance from systemic circulation, as with other beta-blockers, including atenolol, sotalol, metoprolol, and propranolol. It is unlikely that diurnal changes in plasma protein binding due to diurnal changes in plasma protein concentrations are a contributing factor, because timolol is poorly protein bound (7% at 100 ng ml^-1).
Pharmacokinetic parameters for changes in timolol concentration in plasma following intravenous bolus administration of 50 μl of 0.65% timolol maleate solutions

<table>
<thead>
<tr>
<th>Parameter*</th>
<th>0600 Hr</th>
<th>1200 Hr</th>
<th>1800 Hr</th>
<th>2400 Hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>k_{12} (10^{-2} min^{-1})</td>
<td>13.70</td>
<td>4.90</td>
<td>21.60</td>
<td>4.60</td>
</tr>
<tr>
<td>k_{21} (10^{-2} min^{-1})</td>
<td>8.80</td>
<td>5.70</td>
<td>13.00</td>
<td>5.70</td>
</tr>
<tr>
<td>k_{10} (10^{-2} min^{-1})</td>
<td>5.00</td>
<td>4.50</td>
<td>6.70</td>
<td>3.90</td>
</tr>
<tr>
<td>Vdss (L)</td>
<td>6.95</td>
<td>6.28</td>
<td>6.85</td>
<td></td>
</tr>
<tr>
<td>AUC (ng × min/ml)</td>
<td>1014.7 ± 141.7*</td>
<td>1469.9 ± 207.0</td>
<td>827.3 ± 144.2</td>
<td>846.4 ± 87.7</td>
</tr>
<tr>
<td>MRT (min)</td>
<td>33.4 ± 0.89</td>
<td>31.9 ± 2.62</td>
<td>30.0 ± 3.36</td>
<td>35.4 ± 2.21</td>
</tr>
</tbody>
</table>

* See text for explanation of abbreviations.  ^ Mean ± SEM, n = 4.

Gregory and co-workers^{22-24} and others^{19-21} have provided conclusive evidence that the IOP of albino rabbits follows a circadian rhythm that is in phase with the circadian rhythm of aqueous flow.^{22} IOP is high during the dark phase and low during the light phase.^{20,22-24} Experiments are being conducted in the corresponding author's laboratory to determine whether the ocular pharmacokinetics of topically applied timolol also follow a circadian rhythm. This would be shown by dosing time-dependent changes in ocular absorption that vary in phase with the light:dark cycle and must persist in constant dark.

In conclusion, the ratio of ocular:systemic absorption of topically applied timolol in the pigmented rabbit could be improved by varying the time of drop instillation. Although a similar time dependency of ocular and systemic pharmacokinetics may exist in humans, the time at which the above ratio is maximized would probably be different. Studies are in progress to elucidate the mechanisms that cause the variations in ocular and systemic pharmacokinetics of topically applied timolol with the time of drop instillation and to determine whether such variations are circadian.

Key words: chronopharmacokinetics, circadian rhythm, ocular timolol bioavailability, systemic timolol bioavailability, therapeutic index

Acknowledgments

The authors thank Kenneth C. Moy, Samir K. Podder, Ru-Liang Shih, and Roy D. Martinez for technical assistance.

References


